NCT06238167View on ClinicalTrials.gov

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Gastric Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab, 200mg Q3W, max 16 cycles.

DRUG

S-1 therapy

S1 d1-14 bid (\< 1.25m\^2 40mg, 1.25m\^2-1.5m\^2 50mg, ≥ 1.5m\^2 60mg), followed by 7 days off (Q3W, max 16 cycles).

DRUG

low dose SOX therapy

Oxaliplatin: 78mg/m\^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).

All Listed Sponsors
lead

First Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06238167 - Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC | Biotech Hunter | Biotech Hunter